Answers are grounded in this paper and cite their sources.
Medicinal plants have been used from centuries for treating varieties of illnesses.Momordica charantia L. is a widespread medicine as well as vegetative food used traditionally for treating diabetes, bacterial infection, arthritis, malaria, cardiovascular diseases, etc. Due to the lack of biomolecular approaches to M. charantia in the alleviation of hepatitis associated with nonalcoholic fatty liver disease (NAFLD) and liver sinusoidal endothelial cell (LSEC) dysfunction, network pharmacology studies were conducted to determine and validate its biomolecular action.ADME and pharmacokinetics were studied to examine the pharmacokinetic action of its metabolites.The results revealed that M. charantia exhibits a multitherapeutic effect via regulating numerous genes associated with the etiology of NAFLD and thus reducing inflammation, fibrosis, hypertension, obesity, fatty liver disease, diabetes mellitus, and other conditions are all improved.In the pharmacokinetic study, each metabolite of its demonstrated lipophilicity, good gastrointestinal (GI) absorption, and bioavailability.Thus, it is concluded that it also regulated various genomic expressions; namely, CASPs, ILs, MAPKs, AKTs, G6PD, NOs, IL1B, HIF1A, IL6, etc., responsible for hepatic pathophysiological alterations.Furthermore, the evidence signifies the biomolecular approach of M. charantia for alleviating NAFLD and liver sinusoidal endothelial cell dysfunction and provides impactful information for further biomolecular or clinical assessment to enhance the understanding and credibility of present findings.
No takes yet. Share an insight, caveat, or question.
Maryam M. Alnoman (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: